A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

计划入组 1 人 · 首次发布于 2021 年 3 月 10 日

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

计划入组 91 人 · 首次发布于 2022 年 12 月 14 日

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

计划入组 42 人 · 首次发布于 2023 年 10 月 19 日

Treprostinil(Orenitram, Remodulin, Tyvaso, Trepulmix)

C₂₃H₃₄O₅ · Rx

Tobramycin dry powder inhalation (PureIMS)

Hexadecyl-treprostinil

Powder Pharmaceuticals Incorporated

Virgin Islands (British)

Inhalation Sciences Sweden AB

Sweden

AGL Welding Supply Co., Inc.

United States

Insmed's TPIP and Brensocatib Programs Show Promise in Rare Pulmonary Diseases

Insmed to Present TPIP Data at PVRI 2026 Congress, Including Phase 3 PALM-PAH Study Design

Insmed's TPIP Achieves Breakthrough Results in Phase 2b PAH Trial with 35% Reduction in Pulmonary Vascular Resistance